Use of rifampin for severe pruritus in children with chronic cholestasis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 29, Issue 4, 1999, Pages 442-447

  Yerushalmi, Baruch ^a   Sokol, Ronald J ^a   Narkewicz, Michael R ^a   Smith, Debra ^a   Karrer, Frederick M ^b  

^a CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Alagille's syndrome; Bile acids; Biliary atresia; Opioid receptors; Pruritus; Rifampin; Ursodeoxycholic acid

Indexed keywords

DIPHENHYDRAMINE; PHENOBARBITAL; RIFAMPICIN; URSODEOXYCHOLIC ACID;

ALAGILLE SYNDROME; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BILE DUCT ATRESIA; CHILD; CHOLESTASIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INFANT; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHOLESTASIS; CHRONIC DISEASE; FEMALE; HUMANS; INFANT; MALE; PRURITUS; RIFAMPIN; TREATMENT OUTCOME;

EID: 0033505605     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199910000-00013     Document Type: Article

References (30)

1. Garden JM, Ostrow JD, Roenigk HH Jr. Pruritus in hepatic cholestasis: Pathogenesis and therapy. Arch Dermatol 1985;121:1415-20.
2. Connolly CS, Kantor GR, Menduke N. Hepatobiliary pruritus: What are effective treatments? J Am Acad Dermatol 1995;33: 801-5.
3. Donovan G, Kidwell M. Benign recurrent intrahepatic cholestasis: Relief of pruritus with carbamazepine [abstract]. Gastroenterology 1988;94:536.
4. Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985;26:291-4.
5. Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OF. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss. Hepatology 1989;10:420-9.
6. Borgeat A, Wilder-Smith OHG, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993;104:244-7.
7. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, Buuren HRV. Oral naltrexone treatment for cholestatic pruritus: A double blind, placebo-controlled study Gastroenterology 1997; 113:1264-9.
8. Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988;95:130-6.
9. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;2:574-6.
10. Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991;36:216-20.
11. Cynamon HA, Andres JM, Iafrate PR. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990; 98:1013-6.
12. Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch Dis Child 1993;69:141-3.
13. Miguet JP, Mavier P, Soussy CJ, Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampin in man. Gastroenterology 1977;72:924-6.
14. Wietholtz H, Marschall HU, Sjovall J, Matern S. Stimulation of bile acid 6α-hydroxylation by rifampin. J Hepatol 1996;24:713-8.
15. Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat Med 1998;4:92-6.
16. Suchy FJ. Approach to the infant with cholestasis. In: Suchy FJ, ed. Liver disease in children. St. Louis: Mosby, 1994:349-55.
17. Balsells F, Wyllie R, Steffen R, Kay M. Benign recurrent intrahepatic cholestasis: Improvement of pruritus and shortening of the symptomatic phase with rifampin therapy: A case report. Clin Pediatr 1997;36:483-5.
18. Cancado ELR, Leitao RMC, Carrilho FJ, Laudanna AA. Unepected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of γ-glutamyl transpeptidase. Am J Gastroenterol 1998;93:1510-7.
19. Ramirez RO, Sokol RJ. Medical management of cholestasis. In: Suchy FJ, ed. Liver disease in children. St. Louis: Mosby 1994: 356-88.
20. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infec Dis 1983;5:S440-6.
21. Floersheim GL. Suppression of cellular immunity in vivo by rifampin. Experientia 1973;29:1545-6.
22. Mukerjee P, Schuldt S, Kasik JE. Effect of rifampin on cutaneous hypersensitivity to purified protein derivative in humans. Antimicrob Agents Chemother 1973;4:607-11.
23. Nilsson BS. Rifampicin: An immunosuppressant? Lancet 1971;2: 374.
24. Pogo BGT. Specific inhibition by rifampicin of transcription in human lymphocytes stimulated by phytohemagglutinin. J Cell Biol 1972;55:515-9.
25. Jones EA, Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists. Hepatology 1990;11:884-7.
26. Schoenfield LJ, Sjovall J, Perman E. Bile acids on the skin of patients with pruritic hepatobiliary disease. Nature 1967;213:93-4.
27. Bergasa NV, Sabol SL, Young WS III, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995;268:G346-54.
28. Bergasa NV, Vergalla J, Swain MG, Jones EA. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996;16:298-302.
29. Galeazzi R, Corenzini I, Orlandi F. Rifampin-induced elevation of serum bile acids in man. Dig Dis Sci 1980;25:108-12.
30. Walt RP. Effect of stanozolol on itching in primary biliary cirrhosis. BMJ 1988;296:607.